Density gradient separation of carborane-containing liposome from low density lipoprotein and detection by inductively coupled plasma spectrometry

Journal of Liposome Research

Volumn 24, Issue 1, 2014, Pages 53-58

  Alanazi, Fars K ^a,b   Lu, D Robert ^b   Shakeel, Faiyaz ^a,b   Haq, Nazrul ^a,c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b UNIVERSITY OF GEORGIA   (United States)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Boron compound; Inductively coupled plasma; Liposomes; Low density lipoprotein; Ultracentrifugation

Indexed keywords

BORON; CARBORANE DERIVATIVE; CHOLESTERYL 1,12 DICARBA CLOSO DODECACABORANE 1 CARBOXYLATE; CHOLESTERYL 3BETA 12 (1 OCTENYL) 1,12 DICARBO CLOSO DODECACABORANE 1 CARBOXYLATE; CHOLESTERYL 3BETA 12 OCTADECYL 1,12 DICARBO CLOSO DODECACABORANE 1 CARBOXYLATE; CHOLESTERYL 3BETA 12 OCTYL 1,12 DICARBO CLOSO DODECACABORANE 1 CARBOXYLATE; LIPOSOME; LOW DENSITY LIPOPROTEIN; PHOSPHORUS; UNCLASSIFIED DRUG;

ARTICLE; ATOMIC EMISSION SPECTROMETRY; BRAIN TISSUE; CONTROLLED STUDY; DENSITY GRADIENT; DENSITY GRADIENT CENTRIFUGATION; DRUG BRAIN LEVEL; DRUG DETERMINATION; HUMAN; HUMAN TISSUE; LIMIT OF DETECTION; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; TIME; VELOCITY;

BORON COMPOUNDS; CENTRIFUGATION, DENSITY GRADIENT; CHOLESTEROL; DRUG DELIVERY SYSTEMS; HUMANS; LIPOPROTEINS, LDL; LIPOSOMES; SPECTROPHOTOMETRY, ATOMIC;

EID: 84893286226     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.3109/08982104.2013.833224     Document Type: Article

References (22)

1. Alanazi F, Li H, Halpern DS, et al. (2003). Synthesis, preformulation and liposomal formulation of cholesteryl carborane esters with various fatty chains. Int J Pharm 255:189-97.
2. Barth RF. (2003). A critical assessment of boron neutron capture therapy: an overview. J Neurooncol 62:1-5.
3. Barth RF, Coderre JA, Vicente MGH, Blue TE. (2005). Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res 11:3987-4002.
4. Bregadze VI, Sivaev IB, Glazun SA. (2006). Polyhedral boron compounds as potential diagnostic and therapeutic antitumor agents. Anticancer Agents Med Chem 6:75-109.
5. Heyes JA, Niculescu-Duvaz D, Cooper RG, Springer CJ. (2002). Synthesis of novel cationic lipids: effect of structural modification on the efficiency of gene transfer. J Med Chem 45:99-114.
6. Hidalgo FJ, Nogales F, Zamora R. (2004). Determination of pyrrolized phospholipids in oxidized phospholipid vesicles and lipoproteins. Anal Biochem 334:155-63.
7. Hiratsuka J, Yoshino K, Kondoh H, et al. (2000). Biodistribution of boron concentration on melanoma-bearing hamsters after administration of p-, m-, o-boronophenylalanine. Jpn J Cancer Res 91:446-50.
8. Ji B, Peacock G, Lu DR. (2002). Synthesis of cholesterol-carborane conjugate for targeted drug delivery. Bioorg Med Chem Lett 12: 2455-8.
9. Kader A, Davis PJ, Kara M, Liu H. (1998). Drug targeting using lowdensity lipoprotein (LDL): physicochemical factors affecting drug loading into LDL particles. J Control Rel 55:231-43.
10. Kamidate T, Suita T, Watanabe H. (1996). Assay of phosphatidylcholine in liposome suspensions by inductively coupled plasma atomic emission spectrometry with ultrasonic nebulizer. Anal Biochem 241: 264-6.
11. Li F, Goessler W, Irgolic KJ. (1999). Determination of selenium compounds by HPLC with ICP-MS or FAAS as selenium-specific detector. Se Pu 17:240-4.
12. Liu J, Kraut E, Bender J, et al. (2002). Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. Cancer Chemother Pharmacol 49:367-74.
13. Meidan VM, Cohen JS, Amariglio N, et al. (2000). Interaction of oligonucleotides with cationic lipids: the relationship between electrostatics, hydration and state of aggregation. Biochim Biophys Acta 1464: 251-61.
14. Morrison DE, Issa F, Bhadbhade M, et al. (2010). Boronated phosphonium salts containing arylboronic acid, closo-carborane, or nido-carborane: synthesis, X-ray diffraction, in vitro cytotoxicity and cellular uptake. J Biol Inorg Chem 15:1305-18.
15. Shawer M, Greenspan P, Oie S, Lu DR. (2002). VLDL-resembling phospholipid-submicron emulsion for cholesterol-based drug targeting. J Pharm Sci 91:1405-13.
16. Suita T, Kamidate T. (1999). Preparation of antibody-coupled liposomes containing horseradish peroxidase as a marker molecule. Anal Sci 15: 349-52.
17. Svantesson E, Capala J, Markides KE, Pettersson J. (2002). Determination of boron-containing compounds in urine and blood plasma from boron neutron capture therapy patients: the importance of using coupled techniques. Anal Chem 74:5358-63.
18. Valliant JF, Guenther KJ, King AS, et al. (2002). The medicinal chemistry of carboranes. Coord Chem Rev 232:173-230.
19. Versluis AJ, Rump ET, Rensen PC, et al. (1999). Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo. J Pharmacol Exp Ther 289:1-7.
20. Wasan KM, Brazeau GA, Keyhani A, et al. (1993). Roles of liposome composition and temperature in distribution of amphotericin B in serum lipoproteins. Antimicrob Agents Chemother 37:246-50.
21. Wasan KM, Ramasway M, Cassidy SM, et al. (1997). Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma. Antimicrob Agents Chemother 41:1871-5.
22. Zheng J, Shibata Y, Tanaka A. (2002). Study of the stability of selenium compounds in human urine and determination by mixed ion-pair reversed-phase chromatography with ICPMS detection. Anal Bioanal Chem 374:348-53.